We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Positron Emission Tomography and Radioimmunotargeting: General Aspects.
- Authors
Lundqvist, Hans; Lubberink, Mark; Tolmachev, Vladimir; Lövqvist, Anna; Sundin, Anders; Beshara, Soheir; Bruskin, Alexander; Carlsson, Jörgen; Westlin, Jan-Erik
- Abstract
To optimize radioimmunotherapy, in vivo information on individual patients, such as radionuclide uptake, kinetics, metabolic patterns and optimal administration methods, is important. An overriding problem is to determine accurately the absorbed dose in the target organ as well as critical organs. Positron Emission Tomography (PET) is a superior technique to quantify regional kinetics in vivo with a spatial resolution better than 1 cm[sup 3] and a temporal resolution better than 10 s. However, target molecules often have distribution times of several hours to days. Conventional PET nuclides are not applicable and alternative positron-emitting nuclides with matching half-lives and with suitable labelling properties are thus necessary. Over many years we have systematically developed convenient production methods and labelling techniques of suitable positron nuclides, such as [sup 110]In(T½=1.15 h), [sup 86]Y(T½=14 h), [sup 76]Br(T½=16 h) and [sup 124]I(T½=4 days). 'Dose planning' can be done, for example, with [sup 86]Y- or [sup 124]I-labelled ligands before therapy, and [sup 90]Y- and [sup 131]I-labelled analogues and double-labelling, e.g. with a [sup 86]Y/[sup 90]Y-labelled ligand, can be used to determine the true radioactivity integral from a pure beta-emitting nuclide. The usefulness of these techniques was demonstrated in animal and patient studies by halogen-labelled MAbs and EGF-dextran conjugates and peptides chelated with metal ions.
- Subjects
POSITRON emission tomography; RADIOIMMUNOTHERAPY
- Publication
Acta Oncologica, 1999, Vol 38, Issue 3, p335
- ISSN
0284-186X
- Publication type
Article
- DOI
10.1080/028418699431410